Sairopa

Executive Summary

Sairopa is a clinical-stage biotechnology company headquartered in Rotterdam, Netherlands, dedicated to developing novel antibody-based immunotherapies for cancer. Its mission is to modulate the cancer-immunity cycle at multiple points to enhance patients' own immune responses against tumors. The company's pipeline includes proprietary antibodies targeting SIRPalpha and CTLA-4, which aim to improve antigen presentation and T-cell activation, respectively. With a focus on these two immune checkpoints, Sairopa seeks to address key limitations in current immunotherapy approaches. The company is currently in Phase 3 clinical development, indicating progress toward potential registration and commercialization. As a private entity, Sairopa has not disclosed total funding or valuation, but its late-stage pipeline suggests significant investment and momentum. The company's scientific focus and stage position it as a potential player in the competitive immuno-oncology landscape, with opportunities for partnerships or further financing to support regulatory filings and market launch.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 clinical trial data readout for SIRPalpha or CTLA-4 antibody65% success
• Q2 2026Potential partnership or licensing deal for one of the pipeline candidates50% success
• Q4 2026Regulatory submission (e.g., IND or NDA) for lead candidate45% success